TIL for the treatment of patients with solid cancer: an interactive workshop

Personalised T-cell therapy has now reached the solid tumour therapy field as a first of-its-kind immunotherapy for patients with melanoma with an approval granted by the FDA on February 17th  2024.

Imagine the act of walking. It’s something most able-bodied people do without a second thought. Yet it is actually a complex process involving various neurological and physiological systems. PD is a condition where the brain slowly loses specific cells, called dopamine neurons, resulting in reduced strength and speed of movements. However, there’s another important aspect that gets affected: the length of actions. Someone with PD might not only move more slowly but also take fewer steps in a walking sequence or bout before stopping.